CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Collaboration revenue	$ 5,594	$ 6,068
Operating expenses:
Research and development	18,960	10,370
General and administrative	4,423	1,832
Total operating expenses	23,383	12,202
Loss from operations	(17,789)	(6,134)
Other income:
Interest income, net	886	1,063
Total other income, net	886	1,063
Loss before benefit from (provision for) income taxes	(16,903)	(5,071)
Benefit from (provision for) income taxes	157	(129)
Net loss	$ (16,746)	$ (5,200)
Net loss per share, basic and diluted	$ (0.55)	$ (2.77)
Weighted average common shares outstanding, basic and diluted	30,188,575	1,879,986
Comprehensive loss:
Net loss	$ (16,746)	$ (5,200)
Other comprehensive income:
Unrealized holding gains on marketable securities	571	25
Total other comprehensive income	571	25
Comprehensive loss	(16,175)	(5,175)
AbbVie
Collaboration revenue	3,392	5,570
Janssen
Collaboration revenue	$ 2,202	$ 498